Lilly CEO John Lechleiter

Lilly CEO John Lechleiter

Jeff Kowalsky/Bloomberg

Lilly Chief Executive Officer John Lechleiter said that the failure of semagacestat “doesn’t in any way impact our commitment to Alzheimer’s.”